

Andreas Waha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12088558/publications.pdf>

Version: 2024-02-01

72
papers

4,153
citations

126907

33
h-index

114465

63
g-index

73
all docs

73
docs citations

73
times ranked

7379
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. <i>Journal of Neuroimmunology</i> , 2013, 264, 71-83.	2.3	330
2	Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 368-381.	2.8	194
3	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. <i>Neuro-Oncology</i> , 2018, 20, 123-131.	1.2	184
4	Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. <i>Nature Immunology</i> , 2011, 12, 898-907.	14.5	179
5	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. <i>Neuro-Oncology</i> , 2015, 17, 45-52.	1.2	172
6	Elevated Expression of Wnt Antagonists Is a Common Event in Hepatoblastomas. <i>Clinical Cancer Research</i> , 2005, 11, 4295-4304.	7.0	145
7	Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 544-558.	1.7	137
8	Anticancer Effects of Niclosamide in Human Glioblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 4124-4136.	7.0	135
9	Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme. <i>Brain Pathology</i> , 1997, 7, 871-875.	4.1	128
10	Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. <i>Acta Neuropathologica</i> , 2011, 122, 495-510.	7.7	125
11	H3F3A K27M Mutation in Pediatric CNS Tumors. <i>American Journal of Clinical Pathology</i> , 2013, 139, 345-349.	0.7	116
12	Epigenetic Silencing of the Protocadherin Family Member PCDH-13-All in Astrocytomas. <i>Neoplasia</i> , 2005, 7, 193-199.	5.3	102
13	Nuclear Exclusion of TET1 Is Associated with Loss of 5-Hydroxymethylcytosine in IDH1 Wild-Type Gliomas. <i>American Journal of Pathology</i> , 2012, 181, 675-683.	3.8	98
14	Temporal Lobe Epilepsy Associated Up-Regulation of Metabotropic Glutamate Receptors: Correlated Changes in mGluR1 mRNA and Protein Expression in Experimental Animals and Human Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 1-10.	1.7	94
15	High frequency of H3F3A K27M mutations characterizes pediatric and adult high-grade gliomas of the spinal cord. <i>Acta Neuropathologica</i> , 2015, 130, 435-437.	7.7	83
16	Analysis of TET Expression/Activity and 5mC Oxidation during Normal and Malignant Germ Cell Development. <i>PLoS ONE</i> , 2013, 8, e82881.	2.5	80
17	FGFR1 Mutations in Rosette-Forming Glioneuronal Tumors of the Fourth Ventricle. <i>Journal of Neuropathology and Experimental Neurology</i> , 2014, 73, 580-584.	1.7	76
18	Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. <i>Brain Pathology</i> , 2019, 29, 205-216.	4.1	75

#	ARTICLE	IF	CITATIONS
19	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. <i>Journal of Neuro-Oncology</i> , 2010, 97, 389-392.	2.9	72
20	Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. <i>Acta Neuropathologica</i> , 1996, 92, 70-74.	7.7	71
21	Lack of prognostic relevance of alterations in the epidermal growth factor receptor- α transforming growth factor- β pathway in human astrocytic gliomas. <i>Journal of Neurosurgery</i> , 1996, 85, 634-641.	1.6	69
22	Epigenetic Downregulation of Mitogen-Activated Protein Kinase Phosphatase MKP-2 Relieves Its Growth Suppressive Activity in Glioma Cells. <i>Cancer Research</i> , 2010, 70, 1689-1699.	0.9	66
23	H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?. <i>Journal of Neuro-Oncology</i> , 2013, 112, 67-72.	2.9	65
24	Enzymatic Activity of HPGD in Treg Cells Suppresses Tconv Cells to Maintain Adipose Tissue Homeostasis and Prevent Metabolic Dysfunction. <i>Immunity</i> , 2019, 50, 1232-1248.e14.	14.3	63
25	Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. <i>International Journal of Cancer</i> , 2007, 121, 284-291.	5.1	60
26	Epigenetic Silencing of the <i>HIC-1</i> Gene in Human Medulloblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 1192-1201.	1.7	57
27	Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. <i>Journal of Neuroscience Research</i> , 2008, 86, 2450-2461.	2.9	56
28	A systematic search for DNA methyltransferase polymorphisms reveals a rare DNMT3L variant associated with subtelomeric hypomethylation. <i>Human Molecular Genetics</i> , 2009, 18, 1755-1768.	2.9	55
29	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. <i>Journal of Neuro-Oncology</i> , 2016, 127, 435-444.	2.9	55
30	A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 750-756.	2.8	53
31	Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. <i>Journal of Pathology</i> , 2004, 204, 546-554.	4.5	52
32	p57KIP2 Is Not Mutated in Hepatoblastoma but Shows Increased Transcriptional Activity in a Comparative Analysis of the Three Imprinted Genes p57KIP2, IGF2, and H19. <i>American Journal of Pathology</i> , 2000, 157, 1393-1403.	3.8	50
33	Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. <i>British Journal of Cancer</i> , 2019, 121, 545-555.	6.4	49
34	A Rapid and Sensitive Protocol for Competitive Reverse Transcriptase (cRT) PCR Analysis of Cellular Genes. <i>Brain Pathology</i> , 2006, 8, 13-18.	4.1	42
35	Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. , 1998, 78, 306-309.		37
36	Supratentorial ependymoma in childhood: more than just RELA or YAP. <i>Acta Neuropathologica</i> , 2021, 141, 455-466.	7.7	37

#	ARTICLE	IF	CITATIONS
37	Aberrant Methylation and Reduced Expression of LHX9 in Malignant Gliomas of Childhood. <i>Neoplasia</i> , 2009, 11, 700-711.	5.3	36
38	Genome-Wide DNA Copy Number Analysis of Desmoplastic Infantile Astrocytomas and Desmoplastic Infantile Gangliogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 807-815.	1.7	34
39	Genetic Analysis of Diffuse High-Grade Astrocytomas in Infancy Defines a Novel Molecular Entity. <i>Brain Pathology</i> , 2015, 25, 409-417.	4.1	32
40	Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT). <i>Journal of Neuro-Oncology</i> , 2012, 110, 21-25.	2.9	31
41	Variable Imprinting of H19 and IGF2 in Fetal Cerebellum and Medulloblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 1996, 55, 1270-1276.	1.7	30
42	Intramedullary gangliogliomas: histopathologic and molecular features of 25 cases. <i>Human Pathology</i> , 2016, 49, 107-113.	2.0	28
43	A Polymerase Chain Reaction-based Assay for the Rapid Detection of Gene Amplification in Human Tumors. <i>Diagnostic Molecular Pathology</i> , 1996, 5, 147-150.	2.1	27
44	Combination of Hedgehog Signaling Blockage and Chemotherapy Leads to Tumor Reduction in Pancreatic Adenocarcinomas. <i>Pancreas</i> , 2012, 41, 222-229.	1.1	26
45	Expression of galectin-3 in neuronally differentiating PC12 cells is regulated both via Ras/MAPK-dependent and -independent signalling pathways. <i>Journal of Neurochemistry</i> , 2003, 87, 1112-1124.	3.9	25
46	MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays. <i>Genome Biology</i> , 2009, 10, R105.	9.6	25
47	RANK (TNFRSF11A) Is Epigenetically Inactivated and Induces Apoptosis in Gliomas. <i>Neoplasia</i> , 2012, 14, 526-532.	5.3	25
48	Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection. <i>Journal of Neuro-Oncology</i> , 2019, 145, 143-150.	2.9	23
49	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1885-1897.	1.2	23
50	Quality control of astrocyte-directed Cre transgenic mice: The benefits of a direct link between loss of gene expression and reporter activation. <i>Glia</i> , 2009, 57, 680-692.	4.9	22
51	p75 ^{NTR} induces apoptosis in medulloblastoma cells. <i>International Journal of Cancer</i> , 2011, 128, 1804-1812.	5.1	22
52	Prognostic factors in recurrent glioblastoma patients treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2016, 129, 93-100.	2.9	22
53	Analysis of KIAA1549-BRAF fusion status in a case of rosette-forming glioneuronal tumor of the fourth ventricle (RGNT). <i>Neuropathology</i> , 2011, 31, 654-657.	1.2	20
54	FLAIR-Only Progression in Bevacizumab-Treated Relapsing Glioblastoma Does Not Predict Short Survival. <i>Oncology</i> , 2013, 85, 191-195.	1.9	20

#	ARTICLE	IF	CITATIONS
55	Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide. <i>Cancers</i> , 2019, 11, 858.	3.7	20
56	H3F3A-G34R mutant high grade neuroepithelial neoplasms with glial and dysplastic ganglion cell components. <i>Acta Neuropathologica Communications</i> , 2019, 7, 78.	5.2	20
57	Absence of <i>TERT</i> promoter mutations in primary melanocytic tumours of the central nervous system. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 794-797.	3.2	19
58	Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 342-359.	2.7	19
59	Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma—analysis of O ⁶ -methylguanine-DNA methyltransferase status. <i>Journal of Neuro-Oncology</i> , 2009, 92, 227-232.	2.9	18
60	FGFR1 N546K mutation in a case of papillary glioneuronal tumor (PGNT). <i>Acta Neuropathologica</i> , 2014, 127, 935-936.	7.7	18
61	Promoter-specific transcription of the IGF2 gene: a novel rapid, non-radioactive and highly sensitive protocol for mRNA analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 439, 803-807.	2.8	15
62	Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. <i>Modern Pathology</i> , 2009, 22, 1263-1271.	5.5	13
63	Dysembryoplastic Neuroepithelial Tumor of the Septum Pellucidum and the Supratentorial Midline. <i>American Journal of Surgical Pathology</i> , 2016, 40, 806-811.	3.7	13
64	The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1825-1829.	2.5	13
65	New prognostic factor telomerase reverse transcriptase promoter mutation presents without MR imaging biomarkers in primary glioblastoma. <i>Neuroradiology</i> , 2017, 59, 1223-1231.	2.2	12
66	Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL. <i>Anticancer Research</i> , 2016, 36, 4515-4520.	1.1	9
67	Frequent epigenetic inactivation of the chaperone <i>SGNE1</i> in human gliomas. <i>International Journal of Cancer</i> , 2012, 131, 612-622.	5.1	8
68	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status. <i>Pharmaceuticals</i> , 2021, 14, 195.	3.8	7
69	Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas. <i>Oncotarget</i> , 0, 7, 41898-41912.	1.8	7
70	MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motility. <i>Translational Oncology</i> , 2017, 10, 70-79.	3.7	6
71	Methylation Profiling Identifies Epigenetic Markers for High-grade Gliomas. <i>Cancer Genomics and Proteomics</i> , 2004, 1, 209-214.	2.0	3
72	BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi11.	1.2	0